// App-Quantinova.ai

: RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia

Researchers

Presenter

  • Steven Nathan

Principal Investigators

  • Juergen Behr

  • Harold R Collard

  • Vincent Cottin

  • Marius M Hoeper

  • Fernando Martinez

  • Tamera Corte

  • Anne Keogh

  • Hanno Leuchte

  • Nesrin Mogulkoc

  • Silvia Ulrich

  • Wim Wuyts

  • Stephen Malcolm

  • Sukrut Shah

  • Mia Yao

  • Athol Wells

Medical Centers

  • Advanced Lung Disease and Transplant Program, Department of Medicine, Inova Heart and Vascular Institute, Vienna,, VA, United States of America

  • Department of Internal Medicine III, Technical University of Munich, Munich, Germany

  • Department of Respiratory Medicine, Louis Pradel Hospital, Hospices Civils de Lyon, Université Claude Bernard Lyon,, Lyon, France

  • Clinic for Rehabilitative Medicine, Hannover Medical School, Hannover, Germany

  • Department of Medicine, Weill Cornell Medical College, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York,, NY, United States of America

  • Royal Prince Alfred Hospital, The University of Sydney, Sydney, Australia

  • St Vincents Hospital, Sydney, Australia

  • Department of Internal Medicine II, Neuwittelsbach Academic Hospital, Ludwig Maximilians University,, Munich, Germany

  • Ege University Hospital, Pulmonology,, Izmir, Turkey

  • Pulmonology UniversityHospital Zurich, Zurich, Switzerland

  • Unit for Interstitial Lung Diseases, University of Leuven,, Leuven, Belgium

  • Bayer, Berlin, Germany

  • Merck & Co., Inc., Kenilworth, NJ, United States,

  • Bayer Healthcare Co. Ltd, Beijing, China,

  • The Royal Marsden Hospital, London, United Kingdom

Locations

  • United States

  • Germany

  • France

  • Australia

  • Turkey

  • Switzerland

  • Belgium

  • China

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic interstitial pneumonias

  • Pulmonary arterial hypertension

  • Hypertension

Biomarkers

  • N/A

Drug/Treatment

  • Riociguat

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • NA

Study Id's

  • NCT02138825

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved